Biocon Ltd. — Investor Relations & Filings
Biocon Ltd. is a global biopharmaceutical company focused on developing innovative therapies for chronic conditions such as diabetes, oncology, and autoimmune diseases. The company specializes in the research, development, and manufacture of high-quality biosimilars, generic active pharmaceutical ingredients (APIs), and novel biologics. Its portfolio includes recombinant human insulin, insulin analogs, and monoclonal antibodies. Biocon leverages an integrated business model encompassing advanced research and development, large-scale manufacturing, and global commercialization. By prioritizing affordable innovation, the company aims to enhance access to life-saving treatments across international markets, including the United States, Europe, and emerging economies. Its technical expertise in microbial fermentation and complex protein engineering supports a robust pipeline of complex therapeutics designed to address unmet medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Copy of Newspaper Publication | 2026-05-09 | English | |
| Copy of Newspaper Publication | 2026-05-09 | English | |
| Newspaper Advertisement-Postal Ballot Notice | 2026-05-09 | English | |
| Newspaper Advertisement - Financial Results | 2026-05-09 | English | |
| Postal Ballot Notice | 2026-05-08 | English | |
| Shareholders meeting | 2026-05-08 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 44648096 | Copy of Newspaper Publication | 2026-05-09 | English | ||
| 44648098 | Copy of Newspaper Publication | 2026-05-09 | English | ||
| 44723223 | Newspaper Advertisement-Postal Ballot Notice | 2026-05-09 | English | ||
| 44723224 | Newspaper Advertisement - Financial Results | 2026-05-09 | English | ||
| 44723225 | Postal Ballot Notice | 2026-05-08 | English | ||
| 44424232 | Shareholders meeting | 2026-05-08 | English | ||
| 44315704 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-08 | English | ||
| 44723226 | Audio and video recording of Q4 2026 | 2026-05-08 | English | ||
| 43955963 | Investor Presentation | 2026-05-08 | English | ||
| 44723230 | Investor Presentation | 2026-05-08 | English | ||
| 43390572 | Monitoring Agency Report | 2026-05-07 | English | ||
| 44723231 | Outcome of Board Meeting_Monitoring Agency Report | 2026-05-07 | English | ||
| 43348518 | Record Date | 2026-05-07 | English | ||
| 43348530 | Press Release | 2026-05-07 | English | ||
| 43348544 | Outcome of Board Meeting | 2026-05-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
|
Cellectar Biosciences, Inc.
Clinical-stage biopharma developing targeted cancer treatme…
|
CLRB | US | Manufacturing |
|
Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunot…
|
ALCLS | FR | Manufacturing |
Biocon Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61176/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61176 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61176 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61176 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61176}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Biocon Ltd. (id: 61176)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.